Physician profile
Eric C De Warren
NPI 1700848165
$13,165.88
in general payments reported to CMS, 2019-2025
41 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,707 · 2020: $1,139 · 2021: $2,109 · 2022: $2,991 · 2023: $2,910 · 2024: $195 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,219.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,265.00 | 2019-2022 | |
| Novo Nordisk INC | $1,870.39 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,213.14 | 2019-2023 | Farxiga, Breztri |
| Pfizer INC. | $1,201.62 | 2019-2023 | |
| Abbvie INC. | $1,070.76 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Glaxosmithkline, LLC. | $1,058.72 | 2019-2023 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $637.12 | 2019-2023 | Mounjaro, Jardiance |
| Amgen INC. | $372.69 | 2019-2023 | Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $372.68 | 2019-2022 | |
| Daiichi Sankyo INC. | $295.94 | 2021-2022 | |
| Astellas Pharma US INC | $288.74 | 2019-2024 | Veozah |
| Amarin Pharma, INC. | $288.40 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $266.18 | 2019-2023 | Verquvo, Belsomra, Vaxneuvance |
| Bayer Healthcare Pharmaceuticals INC. | $213.01 | 2023 | |
| Novartis Pharmaceuticals Corporation | $170.07 | 2019-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric De Warren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.